Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kura Oncology, Inc. (Nasdaq: KURA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, financial updates and material agreements. As a biopharmaceutical company focused on precision medicines for cancer, Kura uses these filings to report significant events related to its lead menin inhibitor program, KOMZIFTI (ziftomenib), and its broader pipeline.
Recent Form 8-K filings describe key milestones such as full U.S. Food and Drug Administration approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, clinical data from the pivotal KOMET-001 trial, and the wholesale acquisition cost for a one-month supply of KOMZIFTI. Other 8-Ks outline collaboration and co-promotion agreements with Kyowa Kirin, including terms under which Kura leads development, regulatory and commercial strategy in the United States while Kyowa Kirin leads efforts outside the United States.
Filings also cover financial results releases under Item 2.02, inducement equity plans and amendments, and milestone payments associated with the KOMET-017 Phase 3 registrational trials. These documents provide insight into Kura’s commercialization of KOMZIFTI, its clinical development plans for ziftomenib in newly diagnosed and relapsed or refractory AML, and its farnesyl transferase inhibitor programs.
On Stock Titan, investors can review KURA’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes quick views of material events, collaboration structures, and key clinical or regulatory disclosures, helping users navigate detailed 8-Ks and related exhibits without reading every line.
A shareholder of KURA filed a notice of intent to sell up to 11,208 shares of common stock on or about 01/27/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $94,931.76.
The shares relate to restricted stock units that vested on 01/27/2026 in three blocks of 4,096, 2,335, and 4,777 shares acquired from the issuer. The filing notes that there were 88,309,441 shares of this class outstanding and includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Kura Oncology insider plans a small stock sale under Rule 144. A shareholder intends to sell 1,813 shares of Kura Oncology common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $15,356.11.
The filing states that 88,309,441 shares of common stock were outstanding. The shares to be sold were acquired from the issuer as restricted stock units (RSUs) on January 27, 2026, the same date targeted for the sale.
A security holder of KURA has filed a notice of proposed sale of 1,311 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $11,104.17.
The filing states there are 88,309,441 shares of this class outstanding. The seller acquired the 1,311 shares as restricted stock units (RSUs) from the issuer on 01/27/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
Kura Oncology filed a Form 144 notice for a proposed sale of 8,180 shares of its common stock. The shares have an aggregate market value of $69,284.60 and are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ.
The filing states that Kura Oncology had 88,309,441 common shares outstanding as of the time referenced. All 8,180 shares to be sold were acquired on 01/27/2026 from the issuer via restricted stock unit (RSU) transactions on that same date.
A holder of common stock has filed a notice of intent to sell 7,142 shares, with an aggregate market value of $60,492.74. The planned sale is through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an approximate sale date of 01/27/2026. The issuer had 88,309,441 shares outstanding at the time referenced, and the shares to be sold were acquired on 01/27/2026 through multiple RSU grants from the issuer.
Kura Oncology, Inc. filed a current report to furnish a press release dated January 11, 2026. The press release highlights the company’s recent accomplishments, reports preliminary revenue for its product KOMZIFTI™ (ziftomenib), and outlines anticipated milestones for 2026. The press release is attached as Exhibit 99.1. The information provided under Item 2.02 and in Exhibit 99.1 is being furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and will only be incorporated into future Securities Act registration statements if specifically identified.
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni reported new equity awards. On 01/02/2026 she received 50,000 shares of common stock in the form of restricted stock units at a stated price of $0, increasing her directly held common stock to 275,454 shares. The RSUs vest in four equal annual installments on 1/26/2027, 1/26/2028, 1/26/2029 and 1/26/2030, tying the award to multi‑year service.
She was also granted an option to purchase 100,000 shares of common stock at an exercise price of $10.335. This stock option vests in 48 equal monthly installments starting on the grant date and is exercisable until 01/01/2036, providing long-term, performance-linked compensation.
Kura Oncology, Inc. reported an equity award to a senior executive. Chief Scientific Officer Francis Burrows received an option to purchase 185,000 shares of Kura Oncology common stock on January 2, 2026 at an exercise price of $10.335 per share. The option was granted as a new award and is held directly.
The option vests in 48 equal monthly installments starting on the grant date, spreading vesting over four years. It is exercisable until January 1, 2036, and covers 185,000 underlying shares of common stock. Following this grant, Burrows beneficially owns 185,000 derivative securities in the form of this stock option.
Kura Oncology, Inc. (KURA) reported insider equity activity by its Chief Legal Officer on a Form 4. On 11/13/2025, 48,900 shares of common stock were acquired at a price of $0, reflecting vesting tied to performance-based restricted stock units (PSUs). On 11/14/2025, 8,804 shares were sold at $11.1769 in a sell-to-cover transaction for taxes related to this vesting. These PSUs were granted on May 31, 2023 and vest based on specified development milestones and continued service. Following the reported transactions, the officer beneficially owned 188,139 shares of Kura Oncology common stock directly.
Kura Oncology, Inc. (KURA) President and CEO Troy E. Wilson reported the vesting of 182,500 shares of common stock on 11/13/2025. These shares relate to performance-based restricted stock units (PSUs) originally granted on May 31, 2023, which vest upon achievement of specified development milestones and the one-year anniversary of each milestone, subject to continued service. The filing states that the performance criteria for one development milestone were met on November 13, 2025, triggering vesting of one-sixth of the underlying shares at a price of $0 per share. Following this transaction, Wilson beneficially owns 429,353 shares directly, 279,194 shares indirectly through the One Fish Two Fish Revocable Trust, and 300,000 shares indirectly through the Lorax Charitable Remainder Unitrust.